Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits Non-small Cell Lung Cancer

Personalized therapy of advanced non-small cell lung cancer (NSCLC) has been improved by the introduction of EGFR tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. EGFR TKIs induce dramatic objective responses and increase survival in patients bearing sensitizing mutations in the EGFR intr...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Noto, Alessia, De Vitis, Claudia, Roscilli, Giuseppe, Fattore, Luigi, Malpicci, Debora, Marra, Emanuele, Luberto, Laura, D'Andrilli, Antonio, Coluccia, Pierpaolo, Giovagnoli, Maria Rosaria, Normanno, Nicola, Ruco, Luigi, Aurisicchio, Luigi, Mancini, Rita, Ciliberto, Gennaro
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2013
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3787155/
https://ncbi.nlm.nih.gov/pubmed/23896512
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky